BioTelemetry (BEAT) Tops Q3 EPS by 4c

BioTelemetry (NASDAQ: BEAT) reported Q3 EPS of $0.06, $0.04 better than the analyst estimate of $0.02. Revenue for the quarter came in at $43 million versus the consensus estimate of $42 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
• United Community Banks sells equipment finance unit for $1.9 billion